ArticleJournal of clinical neurology (Seoul, Korea)2025
Early Anticoagulation After Large Ischemic Stroke in the Initiation of Anticoagulation After Cardioembolic Stroke Study.
Article in Journal of clinical neurology (Seoul, Korea), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Re: Comments on "Association of Clopidogrel Genetic Polymorphism With Efficacy and Safety for Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Updated Meta-Analysis".Journal of clinical neurology (Seoul, Korea) · 2026Article
- Early Anticoagulation in Large Volume Cardioembolic Stroke: Rethinking the Optimal Initiation Time.Journal of clinical neurology (Seoul, Korea) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
background and purposeClinical trial data indicate that early anticoagulation is generally safe after an ischemic stroke, but there is a paucity of real-world data regarding the safety of early initiation in large strokes. We sought to determine the association between the time to the initiation of anticoagulation and the 90-day risk of recurrent ischemic and major hemorrhagic events.
methodsWe analyzed consecutive patients with an acute large ischemic stroke (volume ≥60 mL) who were included in the multicenter Initiation of Anticoagulation After Cardioembolic Stroke (IAC) study. We assessed recurrent ischemic events (transient ischemic attack, ischemic stroke, and systemic embolism), major hemorrhagic events (symptomatic intracranial hemorrhage [sICH] and major extracranial hemorrhage [ECH]), and the combined outcome within 90 days.
resultsThis study included 155 patients (57.4% females) with a median NIHSS (National Institutes of Health Stroke Scale) score of 14. Only 11 (7.1%) events occurred, comprising 4 (2.6%) ischemic events, 2 (1.3%) sICHs, and 5 (3.2%) major ECHs. The median time to anticoagulation initiation did not differ significantly between subjects with and without recurrent ischemic events (13.5 days versus 9 days,
conclusionsEarly anticoagulation after large ischemic stroke (volume ≥60 mL) in the IAC study was associated with a low risk of sICH and no recurrent ischemic strokes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.